IL2 and lung cancer: A follow-up study demonstrated the cytotoxicity enhancement of TKD (antigenic component of HP70)/IL-2-activated NK cells by PD-1 blocker stimulation, which resulted in local tumor control in immunodeficient and/or immunocompetent mice, in GBM and lung cancer models [48].